Log In
BCIQ
Print this Print this
 

LB-201

  Manage Alerts
Collapse Summary General Information
Company Lixte Biotechnology Holdings Inc.
DescriptionHistone deacetylase (HDAC) inhibitor
Molecular Target Histone deacetylase (HDAC)
Mechanism of ActionHistone deacetylase (HDAC) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today